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Mining gene expression profiles has proven valuable for identifying metagenes, 
defined as linear combinations of individual genes, serving as surrogates of 
biological phenotypes. Typically, such metagenes are jointly generated as the result 
of an optimization process for dimensionality reduction. Here we present an 
unconstrained method for individually generating metagenes that can point to the 
core of the underlying biological mechanisms. We use an iterative process that 
starts from any seed gene and converges to one of several precise attractor 
metagenes representing biomolecular events, such as cell transdifferentiation or 
the presence of an amplicon. By analyzing six rich gene expression datasets from 
three different cancer types, we identified many such biomolecular events, some of 
which are present in all tested cancer types. We focus on several such events 
including a stage-associated mesenchymal transition and a grade-associated 
mitotic chromosomal instability. 
Rich biomolecular datasets, publicly available at an increasing rate from sources such as 
The Cancer Genome Atlas (TCGA), provide unique opportunities for biological 
discovery from purely computational analysis. Gene expression signatures resulting 
from analysis of cancer datasets can serve as surrogates of cancer phenotypes
1
. 
Subtypes in many cancer types
2-4
 have been identified by gene expression analysis often 
using techniques  such as nonnegative matrix factorization
5
 combined with consensus 
clustering
6
. 
The main objective addressed by techniques such as nonnegative matrix 
factorization is to reduce dimensionality by identifying a number of metagenes jointly 
representing the gene expression dataset as accurately as possible, in lieu of the whole 
set of individual genes. Each metagene is defined as a positive linear combination of the 
individual genes, so that its expression level is an accordingly weighted average of the 
expression levels of the individual genes. The identity of each resulting metagene is 
influenced by the presence of other metagenes within the objective of overall 
dimensionality reduction achieved by joint optimization.  
In contrast, if the aim is not dimensionality reduction or classification into 
subtypes, but instead the independent and unconstrained identification of metagenes as 
surrogates of pure biomolecular events, then a different algorithm should be devised. 
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This approach is devoid of cross-interference or mutual exclusivity requirements and 
has the advantage of increasing the chance of precisely identifying the particular genes 
at the core of the underlying biological mechanism as those that have the highest 
weights in the corresponding metagene, thus shedding more light on that mechanism. 
We found that, given a rich dataset represented by a gene expression matrix, such 
surrogate metagenes can be naturally identified as stable and precise attractors using a 
simple iterative approach. This identification is totally unsupervised, as it does not make 
use of any phenotypic association. Once identified, however, a metagene attractor is 
likely to be found associated with a phenotype. 
We found that several attractor metagenes are present in nearly identical form in 
multiple cancer types. This provides an additional opportunity to combine the powers of 
a large number of rich datasets to focus, at an even sharper level, on the core genes of 
the underlying mechanism. For example, this methodology can precisely point to the 
causal (driver) oncogenes within amplicons to be among very few candidate genes. 
Importantly, this can be done from rich gene expression data, which already exist in 
abundance, without making any use of sequencing data.  
We identified many attractors, which can directly lead to corresponding testable 
biological hypotheses. For the purposes of this paper we present the general 
methodology for the benefit of the research community together with a listing of the 
attractors in six datasets from three cancer types (ovarian, colon, breast). We also 
identified other attractors in other cancer types, such as leukemia, consistent with 
known facts about the nature of each disease. Here, we only focus on a few interesting 
cancer-associated attractors that we found present in these three solid cancer types. 
RESULTS 
Derivation of Attractor Metagenes 
Given a nonnegative measure          of pairwise association between genes    and   , 
we define an attractor metagene  ∑       to be a linear combination of the 
individual genes with weights           . The association measure   is assumed to 
have minimum possible value 0 and maximum possible value 1, so the same is true for 
the weights. It is also assumed to be scale-invariant, therefore it is not necessary for the 
weights to be normalized so that they add to 1, and the metagenes can still be thought of 
as expressing a normalized weighted average of the expression levels of the individual 
genes. 
According to this definition, the genes with the highest weights in an attractor 
metagene will have the highest association with the metagene (and, by implication, they 
will tend to be highly associated among themselves) and so they will often represent a 
biomolecular event reflected by the co-expression of these top genes. This can happen, 
e.g., when a biological mechanism is activated, or when a copy number variation 
(CNV), such as an amplicon, is present, in some of the samples included in the 
expression matrix. In the following we use the term “attractor” for simplicity to refer to 
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an attractor metagene, and the term “top genes” to refer to the genes with the highest 
weights in the attractor.  
The definition of an attractor metagene can readily be generalized to include 
features other than gene expression, such as methylation values. It can also be used in 
datasets of any objects (not necessarily genes) characterized by any type of feature 
vectors, with applications in other disciplines, such as social and economic sciences. 
The computational problem of identifying attractor metagenes given an expression 
matrix can be addressed heuristically using a simple iterative process: Starting from a 
particular seed (or “attractee”) metagene M, a new metagene is defined in which the 
new weights are           . The same process is then repeated in the next iteration 
resulting in a new set of weights, and so forth. In all gene expression datasets that we 
tried we found that this process converges to a limited number of stable attractors. Each 
attractor is defined by a precise set of weights, which are reached with high accuracy 
typically within 10 or 20 iterations.   
This algorithmic behavior with nice convergence properties is not surprising, 
because if a metagene contains some co-expressed genes with high weights, then the 
next iteration will naturally “attract” even more genes with the same properties, and so 
forth, until the process will eventually converge to a metagene representing a potential 
underlying biological event reflected by this co-expression. Furthermore, the set of the 
few genes with the highest weight are likely to represent the “heart” (core) of the 
biomolecular event. In support of this concept, the association of any of the top-ranked 
individual genes with the attractor metagene is consistently and significantly higher than 
the pairwise association between any of these genes, suggesting that the set of these top 
genes jointly comprise a proxy representing a biomolecular event better than each of the 
individual genes would. The top genes in the attractors can also serve as readily derived 
modules and we can use them in a complementary manner within the context of 
methods of identifying regulatory modules or other related approaches
7
. 
 Indeed, related versions of the signatures identified by attractors in this paper 
have been previously identified in various contexts, often intermingled with additional 
genes that may be unrelated or weakly related to the main underlying mechanism. 
However, the contribution of our work is that these signatures are recognized as multi-
cancer biomolecular events, sharply pointing to the underlying mechanism. Therefore 
the top genes of the attractors will be appropriate for being used as biomarkers or for 
understanding the underlying biology. For example, one of the attractors that we 
identified (the “mitotic CIN” attractor, described below) has previously been found 
among sets of genes described generally
8
 as “proliferation” or “cell cycle related” 
markers, while the actual attractor points much more sharply to particular elements in 
the structure of the kinetochore.  
A reasonable implementation of an “exhaustive” search is to only consider the 
seed metagenes in which one selected “attractee” gene is assigned a weight of 1 and all 
the other genes are assigned a weight of 0. The metagene resulting from the next 
iteration will then assign high weights to all genes highly associated with the originally 
4 
selected gene, to which we refer as the “attractee gene.” In this way all attractors 
representing biomolecular events characterized by coordinately co-expressed genes will 
be identified when these genes are used as attractees. The computational 
implementation of the algorithm is described in Online Methods. We note that a dual 
method can be used to identify attractor “metasamples” as representatives of subtypes, 
and we can also combine such metasamples with the attractor metagenes in various 
ways to achieve biclustering, but this topic is not examined in this paper.  
 We analyzed six datasets, two from ovarian cancer, two from breast cancer and 
two from colon cancer: 
Dataset Sample Size Platform 
Breast Wang (GSE2034) 286 Affymetrix HG-U133A 
Breast TCGA 536 
Agilent 244K Custom Gene Expression 
G4502A-07-3 
Colon Jorrison (GSE14333) 290 Affymetrix HG-U133Plus 2.0 
Colon TCGA 154 
Agilent 244K Custom Gene Expression 
G4502A-07-3 
Ovarian Tothill (GSE9891) 285 Affymetrix HG-U133Plus 2.0 
Ovarian TCGA 584 Affymetrix HG-U133A 
 
In each case, we identified general and genomically localized attractors and we found 
that many among them appear in similar forms in all six datasets. Following are 
descriptions of some of our results, starting with the three strongest multi-cancer 
attractors. 
Mesenchymal Transition Attractor 
This attractor contains mostly epithelial-mesenchymal transition (EMT)-associated 
genes. Table 1 provides a listing of top 100 genes based on their average mutual 
information (Online Methods) with their corresponding attractor metagenes.  
This is a stage-associated attractor, in which the signature is significantly present 
only when a particular level of invasive stage, specific to each cancer type, has been 
reached. For example, this association can be demonstrated in three cancer datasets 
from different types (breast GSE3893, ovarian TCGA and colon GSE14333) that were 
annotated with clinical staging information: We can create a listing of differentially 
expressed genes, ranked by fold change, when ductal carcinoma in situ (DCIS) 
progresses to invasive ductal carcinoma; ovarian cancer progresses to stage III; and 
colon cancer progresses to stage II. In all three cases, the attractor is highly enriched 
among the top genes. Specifically, among the top 100 differentially expressed genes, the 
number of attractor genes included in Table 1 is 55 in breast cancer, 45 in ovarian 
cancer and 31 in colon cancer. The corresponding P values are 3×10
-109
, 9×10
-83
 and 
5×10
-62
, respectively. 
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This attractor has been previously identified with remarkable accuracy as 
representing a particular kind of mesenchymal transition of cancer cells present in all 
types of solid cancers tested leading to a published list of top 64 genes
9, 10
. Indeed 56 of 
these top 64 genes also appear in Table 1 (P < 10
-127
), and furthermore all top 24 genes 
of Table 1 are among the 64. We found that most of the genes of the signature were 
expressed by the cancer cells themselves, and not by the surrounding stroma, at least in 
a neuroblastoma xenograft model that we tried
10
. We also found that the signature is 
associated with prolonged time to recurrence in glioblastoma
11
. Related versions of the 
same signature were previously found to be associated with resistance to neoadjuvant 
therapy in breast cancer
12
. These results are consistent with the finding that EMT 
induces cancer cells to acquire stem cell properties
13
. It has been hypothesized that EMT 
is a key mechanism for cancer cell invasiveness and motility
14-16
. The attractor, 
however, appears to represent a more general phenomenon of transdifferentiation 
present even in nonepithelial cancers such as neuroblastoma, glioblastoma and Ewing’s 
sarcoma. 
Although similar signatures are often labeled as “stromal,” because they contain 
many stromal markers such as α-SMA and fibroblast activation protein, the fact that 
most of the genes of the signature were expressed by xenografted cancer cells
10
, and not 
by mouse stromal cells, suggests that this particular attractor of coordinately expressed 
genes represents cancer cells having undergone a mesenchymal transition. The signature 
may indicate a non-fibroblastic transition, as occurs in glioblastoma, in which case 
collagen COL11A1 is not co-expressed with the other genes of the attractor. We have 
hypothesized that a full fibroblastic transition of the cancer cells occurs when cancer 
cells encounter adipocytes
10
, in which case they may well assume the duties of 
cancer-associated fibroblasts (CAFs) in some tumors
17
. In that case, the best proxy of 
the signature
9
 is COL11A1 and the strongly co-expressed genes THBS2 and INHBA. 
Indeed, the 64 genes of the previously identified signature were found from 
multi-cancer analysis
9
 as the genes whose expression is consistently most associated 
with that of COL11A1.  
The only EMT-inducing transcription factor found upregulated in the xenograft 
model
10
 is SNAI2 (Slug), and it is also the one most associated with the signature in 
publicly available datasets. We also found that the microRNAs most highly associated 
with this attractor are miR-214, miR-199a, and miR-199b. Interestingly, miR-214 and 
miR-199a were found to be jointly regulated by another EMT-inducing transcription 
factor, TWIST1
18
. 
Mitotic CIN Attractor 
This attractor contains mostly kinetochore-associated genes. Table 2 provides a listing 
of the top 100 genes based on their average mutual information with their corresponding 
attractor metagenes, starting from CENPA, which encodes for a histone H3-like 
centromeric protein. 
Contrary to the stage-associated mesenchymal transition attractor, this is a 
grade-associated attractor, in which the signature is significantly present only when an 
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intermediate level of tumor grade is reached. For example, this association can be 
demonstrated in three cancer datasets from different types (breast GSE3494, ovarian 
TCGA and bladder GSE13507) that were annotated with tumor grade information. We 
can create a listing of differentially expressed genes, ranked by fold change, when grade 
G2 is reached. In all three cases, the attractor is highly enriched among the top genes. 
Specifically, among the top 100 differentially expressed genes, the number of attractor 
genes included Table 2 is 41 in breast cancer, 36 in ovarian cancer and 26 in colon 
cancer. The corresponding P values are 7×10
-73
, 4×10
-61
 and 5×10
-47
, respectively. 
Consistently, a similar “gene expression grade index” signature19 was previously found 
differentially expressed between histologic grade 3 and histologic grade 1 breast cancer 
samples. Furthermore, that same signature
19
 was found capable of reclassifying patients 
with histologic grade 2 tumors into two groups with high versus low risks of recurrence.   
 This attractor is associated with chromosomal instability (CIN), as evidenced 
from the fact that another similar gene set comprising a “signature of chromosomal 
instability”20 was previously derived from multiple cancer datasets purely by identifying 
the genes that are most correlated with a measure of aneuploidy in tumor samples. This 
led to a 70-gene signature referred to as “CIN70.” Indeed 34 of these 70 genes appear in 
Table 2 (P < 10
-61
). However, several top genes of the attractor, such as CENPA, 
KIF2C, BUB1 and CCNA2 are not present in the CIN70 list. Mitotic CIN is increasingly 
recognized
21
 as a widespread multi-cancer phenomenon.   
The attractor is characterized by overexpression of kinetochore-associated 
genes, which is known
22
 to induce CIN for reasons that are not clear. Overexpression of 
several of the genes of the attractor, such as the top gene CENPA
23
, as well as 
MAD2L1
24
 and TPX2
25
, has also been independently previously found associated with 
CIN. Included in the mitotic CIN attractor are key components of mitotic checkpoint 
signaling
26
, such as BUB1B, MAD2L1 (aka MAD2), CDC20, and TTK (aka MSP1). 
Also among the genes in the attractor is MKI67 (aka Ki-67), which has been widely 
used as a proliferation rate marker in cancer. 
 Among transcription factors, we found MYBL2 (aka B-Myb) and FOXM1 to be 
strongly associated with the attractor. They are already known to be sequentially 
recruited to promote late cell cycle gene expression
27
 to prepare for mitosis.  
Inactivation of the retinoblastoma (RB) tumor suppressor promotes CIN
28
 and 
the expression of the attractor signature. Indeed, a similar expression of a “proliferation 
gene cluster
29” was found strongly associated with the human papillomavirus E7 
oncogene, which abrogates RB protein function and activates E2F-regulated genes. 
Consistently, many among the genes of the attractor correspond to E2F pathway genes 
controlling cell division or proliferation. Among the E2F transcription factors, we found 
that E2F8 and E2F7 are most strongly associated with the attractor. 
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A lymphocyte-specific attractor 
This attractor consists mainly of lymphocyte-specific genes with prominent presence of 
CD53, PTPRC, LAPTM5, DOCK2 and LCP2. It is strongly associated
30
  with the 
expression of microRNA miR-142 as well as with particular hypermethylated and 
hypomethylated gene signatures, which we reconfirmed to be consistent methylation 
attractors in cancer methylation data with our methodology. There is also significant 
overlap between the sets of hypomethylated and overexpressed genes, suggesting that 
their expression is triggered by hypomethylation. Gene set enrichment analysis reveals 
that the attractor is found enriched in genes known to be preferentially expressed in 
differentiation into lymphocytes
31
 and is also found occasionally upregulated in various 
cancers.  Table 3 provides a listing of the top 100 genes of the attractor based on their 
average mutual information with their corresponding attractor metagenes. 
 
Chr8q24.3 amplicon attractor 
Amplification in chr8q24 is often associated with cancer because of the presence of the 
MYC (aka c-Myc) oncogene at location 8q24.21. Indeed, MYC is one of 157 genes in 
“amplicon 8q23-q24” previously identified32 in an extensive study of the breast cancer 
“amplicome” derived from 191 samples. 
We found, however, that the core of the amplified genes occurs at location 
8q24.3 and this is, in fact, our most prominent multi-cancer amplicon attractor. The 
main core gene of the attractor appears to be PUF60 (aka FIR). Other consistently 
present top genes are EXOSC4, CYC1, SHARPIN, HSF1, GPR172A. It is known that 
PUF60 can repress c-Myc via its far upstream element (FUSE), although a particular 
isoform was found to have the opposite effect
33
. The other genes may also play 
important roles. For example, HSF1 (heat shock transcription factor 1) has been 
associated with cancer in various ways
34
. It was found
35
 that HSF1 can induce genomic 
instability through direct interaction with CDC20, a key gene of the mitotic CIN 
attractor mentioned above (listed in Table 2). Furthermore, HSF1 was found
36
 required 
for the cell transformation and tumorigenesis induced by the ERBB2 (aka HER2) 
oncogene (see subsequent discussion of HER2 amplicon) responsible for aggressive 
breast tumors. 
The top ten genes of the chr8q24.3 attractor, ranked by the average of the 
highest five values of mutual information, are shown in Table 4. Interestingly, one of 
our identified general attractor corresponds to an aneuploidy involving a whole arm 
amplification of chr8q, which is occasionally present in multiple cancer types, and this 
8q amplification is the most prominent such aneuploidy attractor among all 
chromosomes.  
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Chr17q12 HER2 amplicon attractor 
This amplicon is prominent in breast cancer
37
 and we also found it present in some 
samples of ovarian cancer, but not as much in colon cancer. So we initially used the four 
data sets of breast and ovarian cancer for deriving the attractor. We found that ERBB2 
(aka HER2), STAR3, GRB7 and PGAP3 were the top-ranked genes, consistent with their 
known presence in the amplicon. We also found that gene MIEN1 (aka C17orf37) was 
very highly ranked in the two data sets in which its probe set was present. MIEN1 has 
recently been identified as an important gene within the 17q12 amplicon in various 
cancers including prostate cancer
38
. Therefore, we augmented the choice of datasets to 
the following seven, of which MIEN1 is included in five: breast GSE2034, breast 
GSE32646, breast GSE36771, breast TCGA, ovarian GSE9891, ovarian GSE26193, 
ovarian TCGA. Table 4 shows the top ten genes ranked by the average of the top five 
scores of mutual information in the seven datasets for each gene. The results suggest 
that the above-mentioned five genes, including MIEN1, are consistently strongly 
co-expressed, and therefore are likely “driver” genes in the amplicon.  
In addition to the narrow HER2 amplicon, it is known that sometimes a large amplicon 
extends to more than a million bases containing both HER2 as well as TOP2A (one of 
the genes of the mitotic CIN attractor) at 17q21
39
. We have observed that TOP2A 
indeed appears among the top 50 genes in terms of its association with the attractor in 
breast cancer. HER2/TOP2A co-amplification has been linked with better clinical 
response to therapy.  
 
Estrogen receptor breast cancer attractor 
We found this attractor clearly present only in breast cancer, and therefore we derived it 
using six breast cancer data sets (GSE2034, GSE3494, GSE31448, GSE32646, 
GSE36771, breast TCGA). Table 5 shows the top 50 genes ranked by the average 
mutual information in these datasets, revealing that genes CA12, AGR2, GATA3, 
FOXA1, MLPH and TBC1D9 are strongly co-expressed with the estrogen receptor ESR1 
in the attractor. 
 
Using attractor metagenes as proxies of biomolecular events 
A biomolecular event, whether it is present in multiple cancer types or it is cancer 
specific, can be represented by a “consensus attractor metagene” after analyzing 
multiple datasets. To generate such consensus attractors, we rank individual genes in 
terms of their average mutual information (Online Methods) with the corresponding 
attractor metagenes across all datasets.  
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For example, Figure 1 clarifies the previously reported
40
 observation that breast 
tumors with high chromosomal instability are predominantly of the estrogen receptor 
negative phenotype. The scatter plots of the mitotic CIN and estrogen receptor 
metagenes shown in Figure 1, however, demonstrate that the nature of the association is 
that ER negative tumors have high mitotic chromosomal instability (or equivalently that 
low chromosomal instability implies that the tumor is ER positive), but the reverse 
relationship is not as clear.  
 
DISCUSSION 
Gene expression analysis has resulted in several cancer types being further classified 
into subtypes labeled, e.g. as “mesenchymal” or “proliferative.” Such characterizations, 
however, may sometimes simply reflect the presence of the mesenchymal transition 
attractor or the mitotic chromosomal instability attractor, respectively, in some of the 
analyzed samples. Similar subtype characterizations across cancer types often share 
several common genes, but the consistency of these similarities has not been 
significantly high. 
In contrast, using an unconstrained algorithm independent of subtype 
classification or dimensionality reduction, we identified several attractors exhibiting 
remarkable consistency across many cancer types, suggesting that each of them 
represents a precise biological phenomenon present in multiple cancers. 
We found that the mesenchymal transition attractor is significantly present only 
in samples whose stage designation has exceeded a threshold, but not in all of such 
samples. Similarly, we found that the mitotic chromosomal instability attractor is 
significantly present only in samples whose grade designation has exceeded a threshold, 
but not in all of them. On the other hand, the absence of the mesenchymal transition 
attractor in a profiled high-stage sample (or the absence of the mitotic chromosomal 
instability attractor in a profiled high-grade sample) does not necessarily mean that the 
attractor is not present in other locations of the same tumor. Indeed, it is increasingly 
appreciated
41
 that tumors are highly heterogeneous. Therefore it is possible for the same 
tumor to contain components, in which, e.g., some are migratory having undergone 
mesenchymal transition, some other ones are highly proliferative, etc. If so, attempts for 
subtype classification based on one particular site in a sample may be confusing. 
Similarly, existing molecular marker products make use of multigene assays that 
have been derived from phenotypic associations in particular cancer types. For breast 
cancer, biomarkers such as Oncotype DX
42
 and Mammaprint
43
 contain several genes 
highly ranked in our attractors. For example, most of the genes used for the Oncotype 
DX breast cancer recurrence score directly converge to one of our identified attractors: 
MMP11 to the mesenchymal transition attractor; MKI67 (aka Ki-67), AURKA (aka 
STK15), BIRC5 (aka Survivin), CCNB1, and MYBL2 to the mitotic CIN attractor; CD68 
10 
to the lymphocyte-specific attractor; ERBB2 and GRB7 to the HER2 amplicon attractor; 
and ESR1, SCUBE2, PGR to the estrogen receptor attractor.  
We envision, instead, a “multidimensional” biomarker product that will be 
applicable to multiple cancer types. Each of the dimensions will correspond to a specific 
attractor detected from a sharp choice of the genes at its core, reflecting a precise 
biological attribute of cancer. For example, each relevant amplicon can be identified by 
the coordinate co-expression of the top few genes of the attractor without any need for 
sequencing, and each amplicon will correspond to another dimension. The collection of 
the independent results in many dimensions will provide a clearer diagnostic and 
prognostic image after cleanly distinguishing the contributions of each component. 
Even though molecular marker genes in existing products are often separated into 
groups that are related to our attractor designation, any improvement in diagnostic, 
prognostic, or predictive accuracy resulting from better such group designation and 
better choice of genes in each group would be highly desirable. We hope that the 
computational methodology of identifying the attractors of cancer, as presented here, 
will be valuable in that regard. 
 
  
11 
Figures  
 
 
Figure 1: Scatter plots demonstrating the relationship between mitotic CIN 
attractor and estrogen receptor attractor in breast cancer. The two metagenes were 
defined to be “consensus attractors” after ranking individual genes in terms of their 
average mutual information with the corresponding attractor metagenes, across all 
datasets, and selecting the genes having average mutual information greater than 0.5. 
These criteria led to 47 genes in the consensus mitotic CIN attractor (the top 47 genes in 
Table 2), and ESR1, CA12, AGR2, GATA3, FOXA1, MLPH and TBC1D9 (the top seven 
genes in Table 5) in the consensus estrogen receptor breast cancer attractor. These 
scatter plots reveal that ER-negative breast tumors have high mitotic chromosomal 
instability, but not necessarily vice versa. 
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Tables  
 
Table 1:  Top 100 genes of the mesenchymal transition attractor based on six datasets                 
 
Rank Gene Avg MI Rank Gene Avg MI Rank Gene Avg MI 
1 COL5A2 0.814 34 FN1 0.545 67 SPON2 0.444 
2 VCAN 0.776 35 LRRC15 0.534 68 SPOCK1 0.444 
3 SPARC 0.767 36 COL11A1 0.529 69 COL8A2 0.441 
4 THBS2 0.759 37 ANTXR1 0.529 70 PDPN 0.437 
5 FBN1 0.750 38 RAB31 0.527 71 LHFP 0.436 
6 COL1A2 0.750 39 THY1 0.519 72 GREM1 0.436 
7 COL5A1 0.747 40 NNMT 0.518 73 GFPT2 0.436 
8 FAP 0.734 41 SULF1 0.506 74 TGFB1I1 0.435 
9 AEBP1 0.712 42 LOXL1 0.502 75 C1S 0.433 
10 CTSK 0.709 43 PRRX1 0.502 76 EDNRA 0.433 
11 COL3A1 0.688 44 COL10A1 0.499 77 GAS1 0.431 
12 COL1A1 0.684 45 MXRA8 0.494 78 NOX4 0.431 
13 SERPINF1 0.674 46 WISP1 0.484 79 FBLN2 0.429 
14 COL6A3 0.670 47 RCN3 0.483 80 TCF4 0.428 
15 CDH11 0.663 48 TNFAIP6 0.481 81 NUAK1 0.428 
16 GLT8D2 0.658 49 ECM2 0.480 82 ADAMTS2 0.422 
17 MMP2 0.654 50 HTRA1 0.480 83 NDN 0.419 
18 LUM 0.654 51 EFEMP2 0.478 84 DPYSL3 0.418 
19 DCN 0.650 52 MXRA5 0.474 85 LAMA4 0.418 
20 POSTN 0.631 53 ACTA2 0.472 86 MFAP5 0.418 
21 ADAM12 0.614 54 LOX 0.470 87 LGALS1 0.417 
22 COL6A2 0.609 55 ITGBL1 0.466 88 PLAU 0.417 
23 OLFML2B 0.607 56 PMP22 0.465 89 DSE 0.417 
24 INHBA 0.601 57 PTRF 0.463 90 COLEC12 0.416 
25 FSTL1 0.600 58 CALD1 0.460 91 DACT1 0.415 
26 SNAI2 0.577 59 HEG1 0.458 92 CD248 0.402 
27 CRISPLD2 0.574 60 NID2 0.455 93 COL6A1 0.402 
28 PDGFRB 0.567 61 TAGLN 0.455 94 RARRES2 0.401 
29 PCOLCE 0.566 62 SFRP4 0.451 95 JAM3 0.398 
30 BGN 0.566 63 PALLD 0.450 96 SGCD 0.397 
31 ANGPTL2 0.555 64 OLFML1 0.448 97 EMILIN1 0.394 
32 COPZ2 0.553 65 FILIP1L 0.447 98 ZFPM2 0.394 
33 ASPN 0.547 66 TIMP3 0.445 99 IGFBP7 0.394 
  
  
  
  100 ZEB1 0.394 
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Table 2:  Top 100 genes of the mitotic CIN attractor based on six datasets                 
 
 
Rank Gene Avg MI Rank Gene Avg MI Rank Gene Avg MI 
1 CENPA 0.727 34 EXO1 0.539 67 ESPL1 0.448 
2 MELK 0.679 35 AURKA 0.538 68 FAM64A 0.442 
3 KIF2C 0.667 36 CDKN3 0.538 69 SPAG5 0.436 
4 BUB1 0.664 37 DEPDC1 0.536 70 MYBL2 0.436 
5 KIF4A 0.660 38 RRM2 0.535 71 EZH2 0.432 
6 CCNB2 0.659 39 CDCA8 0.535 72 SMC4 0.432 
7 KIF20A 0.657 40 SPC25 0.534 73 C12orf48 0.431 
8 CCNA2 0.652 41 KIF18A 0.528 74 TACC3 0.429 
9 TTK 0.649 42 PLK1 0.508 75 ASF1B 0.427 
10 CEP55 0.638 43 HMMR 0.506 76 ERCC6L 0.424 
11 CCNB1 0.637 44 TOP2A 0.505 77 TK1 0.422 
12 CDC20 0.623 45 CENPF 0.504 78 TROAP 0.421 
13 NCAPH 0.622 46 ZWINT 0.502 79 RFC4 0.420 
14 BUB1B 0.613 47 RAD51AP1 0.502 80 PLK4 0.420 
15 KIF23 0.602 48 CENPE 0.498 81 MCM6 0.416 
16 KIF11 0.592 49 E2F8 0.496 82 KIAA0101 0.415 
17 BIRC5 0.588 50 MKI67 0.494 83 GINS1 0.408 
18 AURKB 0.588 51 CENPN 0.491 84 BLM 0.406 
19 NUSAP1 0.586 52 CHEK1 0.488 85 CKS2 0.402 
20 TPX2 0.584 53 MAD2L1 0.487 86 MCM2 0.402 
21 RACGAP1 0.583 54 GTSE1 0.477 87 CENPI 0.396 
22 PRC1 0.582 55 DTL 0.475 88 NCAPG2 0.393 
23 ASPM 0.581 56 RAD51 0.474 89 STMN1 0.392 
24 MCM10 0.578 57 SHCBP1 0.468 90 NEIL3 0.389 
25 NEK2 0.573 58 TRIP13 0.468 91 ARHGAP11A 0.387 
26 UBE2C 0.569 59 FBXO5 0.466 92 ATAD2 0.384 
27 FOXM1 0.563 60 FANCI 0.464 93 CDC6 0.383 
28 CDCA3 0.560 61 FEN1 0.463 94 CDC7 0.378 
29 NDC80 0.555 62 CDC25C 0.459 95 CCDC99 0.377 
30 STIL 0.553 63 ECT2 0.459 96 CKS1B 0.375 
31 KIF15 0.553 64 RAD54L 0.458 97 RNASEH2A 0.374 
32 KIF14 0.542 65 PBK 0.456 98 PSRC1 0.373 
33 OIP5 0.540 66 KPNA2 0.453 99 DONSON 0.371 
  
  
  
  100 CDC25A 0.360 
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Table 3:  Top 100 genes of the lymphocyte-specific attractor based on six datasets 
                 
 
Rank 
Gene 
Symbol 
Avg 
MI Rank 
Gene 
Symbol 
Avg 
MI Rank 
Gene 
Symbol 
Avg 
MI 
1 PTPRC 0.782 34 GPR65 0.581 67 NCKAP1L 0.482 
2 CD53 0.768 35 CD52 0.580 68 CD247 0.481 
3 LCP2 0.739 36 GIMAP6 0.579 69 GZMK 0.480 
4 LAPTM5 0.707 37 SLAMF8 0.578 70 SELL 0.479 
5 DOCK2 0.699 38 WIPF1 0.576 71 LY86 0.479 
6 IL10RA 0.699 39 MS4A4A 0.574 72 CCR2 0.479 
7 CYBB 0.698 40 ARHGAP15 0.573 73 ITGAM 0.478 
8 CD48 0.691 41 CLEC4A 0.566 74 CORO1A 0.477 
9 ITGB2 0.679 42 CCL5 0.557 75 LILRB1 0.473 
10 EVI2B 0.675 43 LST1 0.557 76 CD74 0.473 
11 MS4A6A 0.673 44 CD3D 0.544 77 GPR171 0.471 
12 TFEC 0.660 45 FGL2 0.539 78 HLA-DMB 0.469 
13 SLA 0.657 46 FCGR2B 0.532 79 ARHGAP25 0.468 
14 SAMSN1 0.652 47 MYO1F 0.530 80 NCF4 0.468 
15 PLEK 0.649 48 CD163 0.524 81 CSF2RB 0.467 
16 GIMAP4 0.647 49 CLEC7A 0.521 82 IL7R 0.464 
17 GMFG 0.647 50 CCR1 0.517 83 BTK 0.463 
18 EVI2A 0.638 51 HLA-DPA1 0.516 84 CD69 0.463 
19 SRGN 0.637 52 NCF2 0.516 85 HLA-DPB1 0.455 
20 AIF1 0.636 53 RNASE6 0.515 86 ITK 0.454 
21 LAIR1 0.627 54 CD14 0.515 87 TLR1 0.454 
22 FYB 0.625 55 CD4 0.510 88 HLA-DMA 0.451 
23 FCER1G 0.623 56 CD84 0.505 89 LILRB4 0.449 
24 CD86 0.621 57 NKG7 0.504 90 IL2RG 0.447 
25 C3AR1 0.611 58 C1QA 0.503 91 TLR2 0.446 
26 C1QB 0.609 59 TRAF3IP3 0.494 92 ALOX5AP 0.444 
27 CD2 0.606 60 TYROBP 0.492 93 IFI30 0.443 
28 HCLS1 0.599 61 LPXN 0.492 94 IRF8 0.443 
29 HCK 0.592 62 IL2RB 0.490 95 ITGAL 0.441 
30 MNDA 0.588 63 IGSF6 0.488 96 TLR8 0.438 
31 CD37 0.587 64 CD300A 0.488 97 PVRIG 0.437 
32 CCR5 0.585 65 SELPLG 0.488 98 FLI1 0.436 
33 LY96 0.584 66 FCGR2A 0.486 99 HLA-DRA 0.434 
  
  
  
  100 LCK 0.433 
 
 
  
15 
Table 4:  List of top ten genes in the chr8q24.3 and HER2 amplicons 
 
chr8q24.3   HER2    
Gene Avg MI  Gene  Avg MI   
PUF60 0.694  ERBB2 0.729   
EXOSC4 0.655  STARD3 0.710   
SHARPIN 0.635  GRB7 0.641   
GPR172A 0.620  PGAP3 0.636   
CYC1 0.594  MIEN1 0.615   
HSF1 0.571  PSMD3 0.494   
FBXL6 0.567  ORMDL3 0.437   
PYCRL 0.550  GSDMB 0.403   
GPAA1 0.529  MED24 0.354   
SCRIB 0.483  PNMT 0.310   
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Table 5:  Top 50 genes of the estrogen receptor breast cancer attractor 
 
Rank 
Gene 
Symbol Avg MI Rank 
Gene 
Symbol Avg MI 
1 CA12 0.596 26 SLC44A4 0.344 
2 AGR2 0.567 27 SLC7A8 0.339 
3 GATA3 0.553 28 BCL11A 0.338 
4 FOXA1 0.551 29 FBP1 0.338 
5 MLPH 0.521 30 MAGED2 0.336 
6 ESR1 0.519 31 SLC22A5 0.335 
7 TBC1D9 0.502 32 GREB1 0.333 
8 ANXA9 0.443 33 EN1 0.333 
9 DNALI1 0.424 34 PSAT1 0.330 
10 SCUBE2 0.423 35 FOXC1 0.329 
11 NAT1 0.422 36 C6orf211 0.325 
12 XBP1 0.421 37 C6orf97 0.324 
13 TFF3 0.407 38 VGLL1 0.321 
14 ABAT 0.405 39 CLSTN2 0.316 
15 GFRA1 0.397 40 IL6ST 0.309 
16 DNAJC12 0.395 41 CELSR1 0.304 
17 TFF1 0.392 42 TSPAN13 0.302 
18 SLC39A6 0.391 43 EVL 0.302 
19 SPDEF 0.382 44 ACADSB 0.300 
20 ERBB4 0.378 45 SIDT1 0.298 
21 THSD4 0.374 46 PGR 0.296 
22 MAPT 0.354 47 C9orf116 0.296 
23 AR 0.349 48 C14orf45 0.288 
24 DACH1 0.348 49 INPP4B 0.287 
25 MYB 0.348 50 AFF3 0.287 
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ONLINE METHODS 
General attractor finding algorithm 
We chose the association measure          between genes to be a power function with 
exponent a of a normalized estimated information theoretic measure of the mutual 
information
44
         with minimum value 0 and maximum value 1 (see “Mutual 
information estimation” below; more sophisticated related association measures45 can 
also be used, but computational complexity will be prohibitive). In other words, 
 (     )   
        , in which the exponent a can be any nonnegative number. Each 
iteration defines a new metagene in which the weight    for gene   is equal to    
         where M is the immediately preceding metagene. The process is repeated until 
the magnitude of the difference between two consecutive weight vectors is less than a 
threshold, which we chose to be equal to 10
-7
.  
 At one extreme, if a is sufficiently large then each of the seeds will create its 
own single-gene attractor because all other genes will always have near-zero weights. In 
that case, the total number of attractors will be equal to the number of genes. At the 
other extreme, if a is zero then all weights will remain equal to each other representing 
the average of all genes, so there will only be one attractor. The higher the value of a, 
the “sharper” (more focused on its top gene) each attractor will be and the higher the 
total number of attractors will be. As the value of a is gradually decreased, the attractor 
from a particular seed will transform itself, occasionally in a discontinuous manner, thus 
providing insight into potential related biological mechanisms. 
We empirically found that an appropriate choice of a (in the sense of revealing 
single biomolecular events of co-expressed genes) for general attractors is around 5, in 
which case there will typically be approximately 50 to 150 resulting attractors, each 
resulting from many attractee genes. An alternative to the power function can be a 
sigmoid function with varying steepness, but we found that the consistency of the 
resulting attractors was worse in that case.  
 An attractor metagene can also be interpreted as a set of the top genes of the 
attractor that includes only the genes that are significantly associated with the attractor. 
One empirical choice includes the genes whose mutual information (or the z-score 
thereof) with the attractor metagene exceeds a threshold. In fact, the attractor finding 
algorithm itself can be designed to discover attractor gene sets without assigning 
weights to genes. In that case, metagenes are defined as simple averages of the genes in 
a set, and each iteration leads to a new gene set consisting of the new set of top-ranked 
genes in terms of their association with the previous metagene (gene set sizes can be 
constant or adaptively changing). This method, however, has the disadvantage of 
occasionally leading to multiple overlapping attractors. 
 Identified attractors can be ranked in various ways. The “strength of an 
attractor” can be defined as the mutual information between the nth top gene of the 
attractor and the attractor metagene. Indeed, if this measure is high, this implies that at 
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least the top n genes of the attractor are strongly co-expressed. We selected n = 50 as a 
reasonable choice, not too large, but sufficiently so to represent a real complex 
biological phenomenon of co-expression of at least 50 genes. For amplicons, n = 5 is 
sufficient to ensure that the oncogenes are included in the co-expression). We use these 
choices when referring to the strength of an attractor.   
The top genes of many among the found attractors are genomically localized. In 
that case the biomolecular event that they represent is often the presence of a particular 
copy number variation. In the cancer datasets that we tried, this phenomenon almost 
always corresponds to a local amplification event known as an amplicon. We therefore 
also devised a related amplicon-finding algorithm, custom-designed to identify localized 
amplicon-representing attractor metagenes, described below. 
Genomically localized attractor finding algorithm 
To identify genomically localized attractors – almost always amplicons – we use the 
same algorithm but for each seed gene we restrict the set of candidate attractor genes to 
only include those in the local genomic neighbourhood of the gene, and we optimize the 
exponent a so that the strength of the attractor is maximized. Specifically, we sort the 
genes in each chromosome in terms of their genomic location and we only consider the 
genes within a window of size 51, i.e., with 25 genes on each side of the seed gene. We 
further optimize the choice of the exponent   for each seed, by allowing   to range from 
1.0 to 6.0 with step size of 0.5 and selecting the attractor with the highest strength. 
Because the set of allowed genes is different for each seed, the attractors will be 
different from each other, but “neighbouring” attractors will usually be very similar to 
each other. Therefore, following exhaustive attractor finding from each seed gene in a 
chromosome, we apply a filtering algorithm to only select the highest-strength attractor 
in each local genomic region, as follows: For each attractor, we rank all the genes in 
terms of their mutual information with the corresponding attractor metagene and we 
define the range of the attractor to be the chromosomal range of its top 15 genes. If there 
is any other attractor with overlapping range and higher strength, then the former 
attractor is filtered out. This filtering is done in parallel, so elimination of attractors 
occurs simultaneously.  
Mutual information estimation 
Assuming that the continuous expression levels of two genes    and    are governed by 
a joint probability density     with corresponding marginals    and   , the mutual 
information         is defined as the expected value of            ⁄  . It is a non-
negative quantity representing the information that each one of the variables provides 
about the other. The pairwise mutual information has successfully been used as a 
general measure of the correlation between two random variables. We compute mutual 
information with a spline-based estimator
46
 using six bins in each dimension. This 
method divides the observation space into equally spaced bins and blurs the boundaries 
between the bins with spline basis functions using third-order B-splines.  We further 
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normalize the estimated mutual information by dividing by the maximum of the 
estimated         and        , so the maximum possible value of         is 1.  
Pre-processing gene expression datasets  
We used Level 3 data when directly available, and imputed missing values using a 
k-nearest-neighbour algorithm with k = 10, as implemented in R
47
. We normalized the 
other datasets on the Affymetrix platform using the RMA algorithm as implemented in 
the affy package in Bioconductor
48
. To avoid biasing attractor convergence with 
multiple correlated probe sets of the same gene, we summarized the probe set-level 
expression values into the gene-level expression values by taking the mean of the 
expression values of probe sets for the same genes. We used the annotations for the 
probe sets given in the jetset package
49
. 
To investigate the associations between the attractor metagene expression and 
the tumor stage and grade, we used the following annotated gene expression datasets. 
For stage association: Breast (GSE3893), TCGA Ovarian, Colon (GSE14333). For 
grade association: Breast (GSE3494), TCGA Ovarian, Bladder (GSE13507). For Breast 
GSE3494 we used only the samples profiled by U133A arrays. For Breast GSE3893 we 
combined two platforms by taking the intersections of the probes in the U133A and the 
U133Plus 2.0 arrays. For datasets profiled by Affymetrix platforms all the datasets were 
normalized using the RMA algorithm. For Bladder GSE13507 normalization was done 
as provided in the GEO.  
P value evaluation 
P values for gene set enrichment were evaluated with the cumulative hypergeometric 
distribution using the total number of genes in each dataset. 
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